Massachusetts identifies first 2022 U.S. case of monkeypox infection
The Massachusetts Department of Public Health on May 17 said it had confirmed a single case of monkeypox virus infection in a man who had recently traveled to Canada.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
/in Committee for Medicinal Products for Human Use (CHMP), COVID-19 Vaccinations, Europe, European Commission, European Medicines Agency, Marketing Authorization Application (MAA), R&D, Vaccine Companies, ValnevaValneva SE confirmed that the European Medicines Agency accepted the filing of a marketing authorization application (MAA) for the specialty vaccine company’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001.
Report: Pfizer, NIH Discussing Study of Longer Paxlovid Dosing Regimen
/in Antivirals, Clinical Trials, COVID-19 cases, COVID-19 Studies, COVID-19 Therapeutics, Dr. Anthony Fauci (Director), Emergency Use Authorization (EUA), National Institutes of Health, Omicron (B.1.1.529) (South Africa), Paxlovid, Pfizer, R&D, TherapeuticsWith increasing concerns about COVID-19 reinfection, Pfizer and the National Institutes of Health are discussing potential studies regarding a longer treatment period with the antiviral medication Paxlovid.
Greater Than One Appoints New Chief Client Officer
/in Appointments, Customers, Healthcare Communications Agencies, Marketing & Advertising, New Hire, People on the MoveGreater Than One, a full-experience marketing agency focused on healthcare, announced that Bindhu Gopalan was appointed Chief Client Officer. She is responsible for overseeing all client engagements at Greater Than One, with a focus on building better healthcare experiences through the agency’s Capability Convergence model.
As COVID cases rise, U.S. health officials mull widening additional booster eligibility
/in CDC, CDC Director Rochelle Walensky, Coronavirus Disease (COVID-19) Pandemic, COVID-19 booster shots, Hospitalized COVID-19 Patients, United States, White HouseHealth officials are considering extending the eligibility for a second COVID-19 vaccine booster dose to people under 50 amid a steady rise in cases, with the United States seeing a threefold increase over the past month.
Why Pfizer May Be Holding Paxlovid Close to the Chest
/in Antivirals, Bloomberg, Clinical Trials, COVID-19 Therapeutics, Drugs for Neglected Diseases Initiative (DNDi), FDA, Hospitalized COVID-19 Patients, Merck, Molnupiravir, Paxlovid, Pfizer, R&D, Symptoms: Coronavirus Disease 2019 (COVID-19), TherapeuticsReportedly, Pfizer is holding the company’s COVID-19 antiviral therapy Paxlovid under tight control. This is a disappointment to numerous investigators who want to test the antiviral combination therapy with other drugs in case the virus develops resistance to the combo.
COVID is rising in the Americas, virus ‘not going away anytime soon’ – PAHO
/in Brazil, Central America, COVID-19 cases, COVID-19 Deaths, COVID-19 Infections, COVID-19 protocols, COVID-19 vaccination rates, Mask-wearing, North America, Pan-American Health Organization (PAHO), Social Distancing, World Health OrganizationCOVID-19 is on the rise again in the Americas as many countries have abandoned measures like masking and social distancing and many lag in vaccination rates, the Pan American Health Organization (PAHO) said on May 18.
Greece goes after Novartis for alleged bribery and kickbacks
/in Allegations, Bribery, Bribery, Bribery Schemes, Bribery schemes, Bribes, Business, Greece, Kickback Schemes, Kickbacks, Legal, Novartis, Overcharge Probe, Price fixing schemes, Probes, Sandoz, Schemes, TherapeuticsGreece’s Health Minister Thanos Plevris announced plans to sue Novartis over what he alleges are illegal practices. The scandal has been playing out for several years, with Novartis alleged to have paid Greek public officials and health care providers to increase prescriptions for the company’s drugs and maintain higher prices.
Researchers may have unlocked mechanism driving inflammation in rheumatoid arthritis
/in Active Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Atherosclerosis, Atopic Dermatitis (Eczema), Autoinflammatory Diseases, Axial Spondyloarthritis, Crohn's Disease, Immune-Inflammatory Diseases, Immune-Inflammatory Disorders, Inflammatory Diseases, Plaque Psoriasis, Psoriasis, Psoriasis, Psoriatic Arthritis, R&D, Rheumatoid Arthritis, Rheumatoid Arthritis, Scientists, TherapeuticsResearchers at Hokkaido University in Japan, in a collaboration with American scientists, may have identified neural crosstalk as the mechanism that drives widespread inflammation in inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and atherosclerosis.
Study: mRNA vaccines perform better against COVID-19 variants of concern
/in AstraZeneca, BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, COVID-19 Studies, COVID-19 Vaccines, Covid-19 Variants, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Messenger RNA (mRNA) Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemics, Peer-Reviewed Analysis, Pfizer, PLOS Medicine, R&D, SARS-CoV-2 virus, Therapeutics, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus.